Compare, Analyse Dishman Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ADCOCK INGRAM
Jun-14
DISHMAN PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs374349-   
Low Rs129252-   
Sales per share (Unadj.) Rs197.8103.7-  
Earnings per share (Unadj.) Rs21.2-26.1-  
Cash flow per share (Unadj.) Rs34.7-21.7-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.981.4-  
Shares outstanding (eoy) m80.69168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.9 44.0%   
Avg P/E ratio x11.9-11.5 -103.3%  
P/CF ratio (eoy) x7.2-13.9 -52.3%  
Price / Book Value ratio x1.43.7 37.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30650,658 40.1%   
No. of employees `0000.84.3 19.3%   
Total wages/salary Rs m5,3553,179 168.4%   
Avg. sales/employee Rs Th19,252.74,078.4 472.1%   
Avg. wages/employee Rs Th6,459.5740.6 872.2%   
Avg. net profit/employee Rs Th2,064.1-1,027.7 -200.9%   
INCOME DATA
Net Sales Rs m15,96117,508 91.2%  
Other income Rs m265123 216.5%   
Total revenues Rs m16,22617,631 92.0%   
Gross profit Rs m4,103-3,034 -135.2%  
Depreciation Rs m1,091756 144.3%   
Interest Rs m944474 199.1%   
Profit before tax Rs m2,334-4,141 -56.3%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624259 241.0%   
Profit after tax Rs m1,711-4,412 -38.8%  
Gross profit margin %25.7-17.3 -148.4%  
Effective tax rate %26.7-6.2 -427.7%   
Net profit margin %10.7-25.2 -42.5%  
BALANCE SHEET DATA
Current assets Rs m11,01812,823 85.9%   
Current liabilities Rs m9,5177,215 131.9%   
Net working cap to sales %9.432.0 29.4%  
Current ratio x1.21.8 65.1%  
Inventory Days Days110111 99.6%  
Debtors Days Days35124 28.1%  
Net fixed assets Rs m16,3047,475 218.1%   
Share capital Rs m16181 198.6%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,51613,742 105.6%   
Long term debt Rs m4,1894,829 86.8%   
Total assets Rs m29,80525,960 114.8%  
Interest coverage x3.5-7.7 -44.9%   
Debt to equity ratio x0.30.4 82.1%  
Sales to assets ratio x0.50.7 79.4%   
Return on assets %8.9-15.2 -58.7%  
Return on equity %11.8-32.1 -36.7%  
Return on capital %17.5-19.8 -88.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,7861,494 186.4%  
From Investments Rs m-1,529-459 333.2%  
From Financial Activity Rs m-9414,383 -21.5%  
Net Cashflow Rs m3165,418 5.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.81 Rs / ZAR

Compare DISHMAN PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: PLETHICO PHARMA  ABBOTT INDIA  FULFORD INDIA  ORCHID PHARMA LTD  SUVEN LIFESCIENCES  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views On News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Two Stocks to Buy in the Great Indian Festival (Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS